Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
Smaranda Gliga, Nadine Lübke, Alexander Killer, Henning Gruell, Andreas Walker, Alexander T Dilthey, Alexander Thielen, Carolin Lohr, Charlotte Flaßhove, Sarah Krieg, Joanna Ventura Pereira, Tobias Paul Seraphin, Alex Zaufel, Martin Däumer, Hans-Martin Orth, Torsten Feldt, Johannes G Bode, Florian Klein, Jörg Timm, Tom Luedde, Björn-Erik Ole Jensen
Clinical Infectious Diseases, doi:10.1093/cid/ciac802
Background. Monoclonal antibodies (mAbs) that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron variants. Immunocompromised patients often experience prolonged viral shedding, resulting in an increased risk of viral escape. Methods. In an observational, prospective cohort, 57 patients infected with Omicron variants who received sotrovimab alone or in combination with remdesivir were followed. The study end points were a decrease in SARS-CoV-2 RNA <10 6 copies/mL in nasopharyngeal swabs at day 21 and the emergence of escape mutations at days 7, 14, and 21 after sotrovimab administration. All SARS-CoV-2 samples were analyzed using whole-genome sequencing. Individual variants within the quasispecies were subsequently quantified and further characterized using a pseudovirus neutralization assay. Results. The majority of patients (43 of 57, 75.4%) were immunodeficient, predominantly due to immunosuppression after organ transplantation or hematologic malignancies. Infections by Omicron/BA.1 comprised 82.5%, while 17.5% were infected by Omicron/ BA.2. Twenty-one days after sotrovimab administration, 12 of 43 (27.9%) immunodeficient patients had prolonged viral shedding compared with 1 of 14 (7.1%) immunocompetent patients (P = .011). Viral spike protein mutations, some specific for Omicron (e.g., P337S and/or E340D/V), emerged in 14 of 43 (32.6%) immunodeficient patients, substantially reducing sensitivity to sotrovimab in a pseudovirus neutralization assay. Combination therapy with remdesivir significantly reduced emergence of escape variants. Conclusions. Immunocompromised patients face a considerable risk of prolonged viral shedding and emergence of escape mutations after early therapy with sotrovimab. These findings underscore the importance of careful monitoring and the need for dedicated clinical trials in this patient population.
Supplementary Data Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
References
Abdullah, Myers, Basu, Decreased severity of disease during the first global Omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa, Int J Infect Dis,
doi:10.1016/j.ijid.2021.12.357Author Contributions, for conceptualization and supervised the study
Bruel, Hadjadj, Maes, Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies, Nat Med,
doi:10.1038/s41591-022-01792-5Choi, Choudhary, Regan, Persistence and evolution of SARS-CoV-2 in an immunocompromised host, N Engl J Med,
doi:10.1056/NEJMc2031364Corey, Beyrer, Cohen, Michael, Bedford et al., SARS-CoV-2 variants in patients with immunosuppression, N Engl J Med,
doi:10.1056/NEJMsb2104756Destras, Bal, Simon, Lina, Josset, Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients, Lancet Microbe,
doi:10.1016/s2666-5247(22)00120-3Gandhi, Klein, Robertson, De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report, Nat Commun,
doi:10.1038/s41467-022-29104-yGroup, Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial, Lancet Infect Dis,
doi:10.1016/S1473-3099(21)00751-9Gupta, Gonzalez-Rojas, Juarez, Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med,
doi:10.1056/NEJMoa2107934Gupta, Gonzalez-Rojas, Juarez, Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2022.2832Hoffmann, Kruger, Schulz, The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic, Cell,
doi:10.1016/j.cell.2021.12.032Jefferson, Spencer, Brassey, Heneghan, Viral cultures for coronavirus disease 2019 infectivity assessment: a systematic review, Clin Infect Dis,
doi:10.1093/cid/ciaa1764Jensen, Luebke, Feldt, Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany, Lancet Reg Health Eur,
doi:10.1016/j.lanepe.2021.100164Leung, Chorlton, Tyson, COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report, Int J Infect Dis,
doi:10.1016/j.ijid.2021.10.045Martin-Blondel, Marcelin, Soulie, Outcome of very high-risk patients treated by sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study), J Infect,
doi:10.1016/j.jinf.2022.04.010Peiffer-Smadja, Bridier-Nahmias, Ferre, Emergence of E484K mutation following bamlanivimab monotherapy among high-risk patients infected with the Alpha variant of SARS-CoV-2, Viruses,
doi:10.3390/v13081642Rockett, Basile, Maddocks, Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use, N Engl J Med,
doi:10.1056/NEJMc2120219Singh, Sharma, Lee, Yadav, SARS-CoV-2: recent variants and clinical efficacy of antibody-based therapy, Front Cell Infect Microbiol,
doi:10.3389/fcimb.2022.839170Solera, Arbol, Alshahrani, Impact of vaccination and early monoclonal antibody therapy on COVID-19 outcomes in organ transplant recipients during the Omicron wave, Clin Infect Dis,
doi:10.1093/cid/ciac324Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2, N Engl J Med,
doi:10.1056/NEJMc2201933Tallarita, Giardina, Novazzi, Spread of multiple SARS-CoV-2 lineages April-August 2020 anticipated the second pandemic wave in Lombardy (Italy), Pediatr Allergy Immunol,
doi:10.1111/pai.13641Truong, Ryutov, Pandey, Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series, EBioMedicine,
doi:10.1016/j.ebiom.2021.103355Vellas, Bello, Debard, Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies, Clin Microbiol Infect,
doi:10.1016/j.cmi.2021.09.008Vellas, Tremeaux, Bello, Resistance mutations in SARS-CoV-2 Omicron variant in patients treated with sotrovimab, Clin Microbiol Infect,
doi:10.1016/j.cmi.2022.05.002Yamasoba, Kosugi, Kimura, Neutralisation sensitivity of SARS-CoV-2 Omicron subvariants to therapeutic monoclonal antibodies, Lancet Infect Dis,
doi:10.1016/S1473-3099(22)00365-6{ 'DOI': '10.1093/cid/ciac802',
'ISSN': ['1058-4838', '1537-6591'],
'URL': 'http://dx.doi.org/10.1093/cid/ciac802',
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:sec>\n'
' <jats:title>Background</jats:title>\n'
' <jats:p>Monoclonal antibodies (mAbs) that target severe acute respiratory '
'syndrome coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron '
'variants. Immunocompromised patients often experience prolonged viral shedding, resulting in '
'an increased risk of viral escape.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Methods</jats:title>\n'
' <jats:p>In an observational, prospective cohort, 57 patients infected with '
'Omicron variants who received sotrovimab alone or in combination with remdesivir were '
'followed. The study end points were a decrease in SARS-CoV-2 RNA &lt;106 copies/mL in '
'nasopharyngeal swabs at day 21 and the emergence of escape mutations at days 7, 14, and 21 '
'after sotrovimab administration. All SARS-CoV-2 samples were analyzed using whole-genome '
'sequencing. Individual variants within the quasispecies were subsequently quantified and '
'further characterized using a pseudovirus neutralization assay.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Results</jats:title>\n'
' <jats:p>The majority of patients (43 of 57, 75.4%) were immunodeficient, '
'predominantly due to immunosuppression after organ transplantation or hematologic '
'malignancies. Infections by Omicron/BA.1 comprised 82.5%, while 17.5% were infected by '
'Omicron/BA.2. Twenty-one days after sotrovimab administration, 12 of 43 (27.9%) '
'immunodeficient patients had prolonged viral shedding compared with 1 of 14 (7.1%) '
'immunocompetent patients (P = .011). Viral spike protein mutations, some specific for Omicron '
'(e.g., P337S and/or E340D/V), emerged in 14 of 43 (32.6%) immunodeficient patients, '
'substantially reducing sensitivity to sotrovimab in a pseudovirus neutralization assay. '
'Combination therapy with remdesivir significantly reduced emergence of escape '
'variants.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Conclusions</jats:title>\n'
' <jats:p>Immunocompromised patients face a considerable risk of prolonged '
'viral shedding and emergence of escape mutations after early therapy with sotrovimab. These '
'findings underscore the importance of careful monitoring and the need for dedicated clinical '
'trials in this patient population.</jats:p>\n'
' </jats:sec>',
'author': [ { 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'},
{ 'name': 'Institute of Virology, University Hospital Düsseldorf, Medical '
'Faculty, Heinrich-Heine-University Düsseldorf , Düsseldorf , '
'Germany'}],
'family': 'Gliga',
'given': 'Smaranda',
'sequence': 'first'},
{ 'ORCID': 'http://orcid.org/0000-0003-3820-7915',
'affiliation': [ { 'name': 'Institute of Virology, University Hospital Düsseldorf, Medical '
'Faculty, Heinrich-Heine-University Düsseldorf , Düsseldorf , '
'Germany'}],
'authenticated-orcid': False,
'family': 'Lübke',
'given': 'Nadine',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Killer',
'given': 'Alexander',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Institute of Virology, Faculty of Medicine and University '
'Hospital Cologne, University of Cologne , Cologne , Germany'}],
'family': 'Gruell',
'given': 'Henning',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Institute of Virology, University Hospital Düsseldorf, Medical '
'Faculty, Heinrich-Heine-University Düsseldorf , Düsseldorf , '
'Germany'}],
'family': 'Walker',
'given': 'Andreas',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Institute of Medical Microbiology and Hospital Hygiene, Medical '
'Faculty, Heinrich-Heine-University Düsseldorf , Düsseldorf , '
'Germany'}],
'family': 'Dilthey',
'given': 'Alexander T',
'sequence': 'additional'},
{ 'affiliation': [{'name': 'Institute of Immunology and Genetics , Kaiserslautern , Germany'}],
'family': 'Thielen',
'given': 'Alexander',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Lohr',
'given': 'Carolin',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Flaßhove',
'given': 'Charlotte',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Krieg',
'given': 'Sarah',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Pereira',
'given': 'Joanna Ventura',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Seraphin',
'given': 'Tobias Paul',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Zaufel',
'given': 'Alex',
'sequence': 'additional'},
{ 'affiliation': [{'name': 'Institute of Immunology and Genetics , Kaiserslautern , Germany'}],
'family': 'Däumer',
'given': 'Martin',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Orth',
'given': 'Hans-Martin',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Feldt',
'given': 'Torsten',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Bode',
'given': 'Johannes G',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Institute of Virology, Faculty of Medicine and University '
'Hospital Cologne, University of Cologne , Cologne , Germany'},
{ 'name': 'Center for Molecular Medicine Cologne, University of Cologne , '
'Cologne , Germany'}],
'family': 'Klein',
'given': 'Florian',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Institute of Virology, University Hospital Düsseldorf, Medical '
'Faculty, Heinrich-Heine-University Düsseldorf , Düsseldorf , '
'Germany'}],
'family': 'Timm',
'given': 'Jörg',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Luedde',
'given': 'Tom',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Gastroenterology, Hepatology and Infectious '
'Diseases, University Hospital Düsseldorf, Medical Faculty, '
'Heinrich-Heine-University Düsseldorf, Düsseldorf, \xa0 Germany'}],
'family': 'Jensen',
'given': 'Björn-Erik Ole',
'sequence': 'additional'}],
'container-title': 'Clinical Infectious Diseases',
'content-domain': {'crossmark-restriction': False, 'domain': []},
'created': {'date-parts': [[2022, 9, 30]], 'date-time': '2022-09-30T20:31:10Z', 'timestamp': 1664569870000},
'deposited': { 'date-parts': [[2022, 11, 2]],
'date-time': '2022-11-02T17:38:38Z',
'timestamp': 1667410718000},
'funder': [ {'award': ['01KX2021'], 'name': 'COVIM'},
{ 'DOI': '10.13039/501100002347',
'doi-asserted-by': 'crossref',
'name': 'Federal Ministry of Education and Research'},
{ 'DOI': '10.13039/501100000780',
'award': ['101046016'],
'doi-asserted-by': 'crossref',
'name': 'European Commission'},
{'name': 'Ministry of Culture and Science of the State of North Rhine-Westphalia'}],
'indexed': { 'date-parts': [[2022, 12, 20]],
'date-time': '2022-12-20T17:18:27Z',
'timestamp': 1671556707887},
'is-referenced-by-count': 2,
'issued': {'date-parts': [[2022, 10, 3]]},
'language': 'en',
'license': [ { 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/',
'content-version': 'am',
'delay-in-days': 0,
'start': { 'date-parts': [[2022, 10, 3]],
'date-time': '2022-10-03T00:00:00Z',
'timestamp': 1664755200000}}],
'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac802/46752524/ciac802.pdf',
'content-type': 'application/pdf',
'content-version': 'am',
'intended-application': 'syndication'},
{ 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac802/46752524/ciac802.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'member': '286',
'original-title': [],
'prefix': '10.1093',
'published': {'date-parts': [[2022, 10, 3]]},
'published-online': {'date-parts': [[2022, 10, 3]]},
'publisher': 'Oxford University Press (OUP)',
'reference': [ { 'DOI': '10.1002/14651858.CD013825.pub2',
'article-title': 'SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19',
'author': 'Kreuzberger',
'doi-asserted-by': 'publisher',
'journal-title': 'Cochrane Database Syst Rev',
'key': '2022110217382301200_ciac802-B1',
'volume': '9',
'year': '2021'},
{ 'DOI': '10.1016/j.cell.2021.12.032',
'article-title': 'The Omicron variant is highly resistant against antibody-mediated '
'neutralization: implications for control of the COVID-19 pandemic',
'author': 'Hoffmann',
'doi-asserted-by': 'publisher',
'first-page': '447',
'journal-title': 'Cell',
'key': '2022110217382301200_ciac802-B2',
'volume': '185',
'year': '2022'},
{ 'DOI': '10.1056/NEJMoa2107934',
'article-title': 'Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody '
'sotrovimab',
'author': 'Gupta',
'doi-asserted-by': 'publisher',
'first-page': '1941',
'journal-title': 'N Engl J Med',
'key': '2022110217382301200_ciac802-B3',
'volume': '385',
'year': '2021'},
{ 'DOI': '10.1001/jama.2022.2832',
'article-title': 'Effect of sotrovimab on hospitalization or death among high-risk '
'patients with mild to moderate COVID-19: a randomized clinical trial',
'author': 'Gupta',
'doi-asserted-by': 'publisher',
'first-page': '1236',
'journal-title': 'JAMA',
'key': '2022110217382301200_ciac802-B4',
'volume': '327',
'year': '2022'},
{ 'DOI': '10.1016/S1473-3099(22)00365-6',
'article-title': 'Neutralisation sensitivity of SARS-CoV-2 Omicron subvariants to '
'therapeutic monoclonal antibodies',
'author': 'Yamasoba',
'doi-asserted-by': 'publisher',
'first-page': '942',
'journal-title': 'Lancet Infect Dis',
'key': '2022110217382301200_ciac802-B5',
'volume': '22',
'year': '2022'},
{'key': '2022110217382301200_ciac802-B6'},
{ 'DOI': '10.1016/S1473-3099(21)00751-9',
'article-title': 'Efficacy and safety of two neutralising monoclonal antibody therapies, '
'sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with '
'COVID-19 (TICO): a randomised controlled trial',
'author': 'Group AC-TfIwC-S',
'doi-asserted-by': 'publisher',
'first-page': '622',
'journal-title': 'Lancet Infect Dis',
'key': '2022110217382301200_ciac802-B7',
'volume': '22',
'year': '2022'},
{ 'DOI': '10.1016/j.jinf.2022.04.010',
'article-title': 'Outcome of very high-risk patients treated by sotrovimab for '
'mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS '
'0003S COCOPREV study)',
'author': 'Martin-Blondel',
'doi-asserted-by': 'publisher',
'first-page': 'e101',
'journal-title': 'J Infect',
'key': '2022110217382301200_ciac802-B8',
'volume': '84',
'year': '2022'},
{ 'DOI': '10.1093/cid/ciac324',
'article-title': 'Impact of vaccination and early monoclonal antibody therapy on COVID-19 '
'outcomes in organ transplant recipients during the Omicron wave',
'author': 'Solera',
'doi-asserted-by': 'publisher',
'journal-title': 'Clin Infect Dis',
'key': '2022110217382301200_ciac802-B9'},
{ 'DOI': '10.1016/j.lanepe.2021.100164',
'article-title': 'Emergence of the E484K mutation in SARS-COV-2-infected '
'immunocompromised patients treated with bamlanivimab in Germany',
'author': 'Jensen',
'doi-asserted-by': 'publisher',
'first-page': '100164',
'journal-title': 'Lancet Reg Health Eur',
'key': '2022110217382301200_ciac802-B10',
'volume': '8',
'year': '2021'},
{ 'DOI': '10.1016/s2666-5247(22)00120-3',
'article-title': 'Sotrovimab drives SARS-CoV-2 Omicron variant evolution in '
'immunocompromised patients',
'author': 'Destras',
'doi-asserted-by': 'publisher',
'first-page': 'e559',
'journal-title': 'Lancet Microbe',
'key': '2022110217382301200_ciac802-B11',
'volume': '3',
'year': '2022'},
{ 'DOI': '10.1016/j.cmi.2022.05.002',
'article-title': 'Resistance mutations in SARS-CoV-2 Omicron variant in patients treated '
'with sotrovimab',
'author': 'Vellas',
'doi-asserted-by': 'publisher',
'first-page': '1297',
'journal-title': 'Clin Microbiol Infect',
'key': '2022110217382301200_ciac802-B12',
'volume': '28',
'year': '2022'},
{ 'DOI': '10.1093/cid/ciaa1764',
'article-title': 'Viral cultures for coronavirus disease 2019 infectivity assessment: a '
'systematic review',
'author': 'Jefferson',
'doi-asserted-by': 'publisher',
'first-page': 'e3884',
'journal-title': 'Clin Infect Dis',
'key': '2022110217382301200_ciac802-B13',
'volume': '73',
'year': '2021'},
{ 'DOI': '10.1111/pai.13641',
'article-title': 'Spread of multiple SARS-CoV-2 lineages April-August 2020 anticipated '
'the second pandemic wave in Lombardy (Italy)',
'author': 'Tallarita',
'doi-asserted-by': 'publisher',
'first-page': '89',
'issue': '(Suppl 27)',
'journal-title': 'Pediatr Allergy Immunol',
'key': '2022110217382301200_ciac802-B14',
'volume': '33',
'year': '2022'},
{ 'DOI': '10.1016/j.ijid.2021.12.357',
'article-title': 'Decreased severity of disease during the first global Omicron variant '
'covid-19 outbreak in a large hospital in Tshwane, South Africa',
'author': 'Abdullah',
'doi-asserted-by': 'publisher',
'first-page': '38',
'journal-title': 'Int J Infect Dis',
'key': '2022110217382301200_ciac802-B15',
'volume': '116',
'year': '2022'},
{ 'DOI': '10.1038/s41591-022-01792-5',
'article-title': 'Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in '
'patients receiving monoclonal antibodies',
'author': 'Bruel',
'doi-asserted-by': 'publisher',
'first-page': '1297',
'journal-title': 'Nat Med',
'key': '2022110217382301200_ciac802-B16',
'volume': '28',
'year': '2022'},
{ 'DOI': '10.1056/NEJMc2201933',
'article-title': 'Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant '
'BA.2',
'author': 'Takashita',
'doi-asserted-by': 'publisher',
'first-page': '1475',
'journal-title': 'N Engl J Med',
'key': '2022110217382301200_ciac802-B17',
'volume': '386',
'year': '2022'},
{'key': '2022110217382301200_ciac802-B18'},
{ 'DOI': '10.1056/NEJMc2031364',
'article-title': 'Persistence and evolution of SARS-CoV-2 in an immunocompromised host',
'author': 'Choi',
'doi-asserted-by': 'publisher',
'first-page': '2291',
'journal-title': 'N Engl J Med',
'key': '2022110217382301200_ciac802-B19',
'volume': '383',
'year': '2020'},
{ 'DOI': '10.1056/NEJMsb2104756',
'article-title': 'SARS-CoV-2 variants in patients with immunosuppression',
'author': 'Corey',
'doi-asserted-by': 'publisher',
'first-page': '562',
'journal-title': 'N Engl J Med',
'key': '2022110217382301200_ciac802-B20',
'volume': '385',
'year': '2021'},
{ 'DOI': '10.1016/j.ebiom.2021.103355',
'article-title': 'Increased viral variants in children and young adults with impaired '
'humoral immunity and persistent SARS-CoV-2 infection: a consecutive '
'case series',
'author': 'Truong',
'doi-asserted-by': 'publisher',
'first-page': '103355',
'journal-title': 'EBioMedicine',
'key': '2022110217382301200_ciac802-B21',
'volume': '67',
'year': '2021'},
{ 'DOI': '10.1038/s41467-022-29104-y',
'article-title': 'De novo emergence of a remdesivir resistance mutation during treatment '
'of persistent SARS-CoV-2 infection in an immunocompromised patient: a '
'case report',
'author': 'Gandhi',
'doi-asserted-by': 'publisher',
'first-page': '1547',
'journal-title': 'Nat Commun',
'key': '2022110217382301200_ciac802-B22',
'volume': '13',
'year': '2022'},
{ 'DOI': '10.1016/j.ijid.2021.10.045',
'article-title': 'COVID-19 in an immunocompromised host: persistent shedding of viable '
'SARS-CoV-2 and emergence of multiple mutations: a case report',
'author': 'Leung',
'doi-asserted-by': 'publisher',
'first-page': '178',
'journal-title': 'Int J Infect Dis',
'key': '2022110217382301200_ciac802-B23',
'volume': '114',
'year': '2022'},
{ 'DOI': '10.1016/j.cmi.2021.09.008',
'article-title': 'Influence of treatment with neutralizing monoclonal antibodies on the '
'SARS-CoV-2 nasopharyngeal load and quasispecies',
'author': 'Vellas',
'doi-asserted-by': 'publisher',
'first-page': '139.e5',
'journal-title': 'Clin Microbiol Infect',
'key': '2022110217382301200_ciac802-B24',
'volume': '28',
'year': '2022'},
{ 'DOI': '10.1056/NEJMc2120219',
'article-title': 'Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use',
'author': 'Rockett',
'doi-asserted-by': 'publisher',
'first-page': '1477',
'journal-title': 'N Engl J Med',
'key': '2022110217382301200_ciac802-B25',
'volume': '386',
'year': '2022'},
{ 'DOI': '10.3389/fcimb.2022.839170',
'article-title': 'SARS-CoV-2: recent variants and clinical efficacy of antibody-based '
'therapy',
'author': 'Singh',
'doi-asserted-by': 'publisher',
'first-page': '839170',
'journal-title': 'Front Cell Infect Microbiol',
'key': '2022110217382301200_ciac802-B26',
'volume': '12',
'year': '2022'},
{ 'DOI': '10.3390/v13081642',
'article-title': 'Emergence of E484K mutation following bamlanivimab monotherapy among '
'high-risk patients infected with the Alpha variant of SARS-CoV-2',
'author': 'Peiffer-Smadja',
'doi-asserted-by': 'publisher',
'first-page': '1642',
'journal-title': 'Viruses',
'key': '2022110217382301200_ciac802-B27',
'volume': '13',
'year': '2021'},
{ 'DOI': '10.1016/B978-0-12-809633-8.20958-8',
'article-title': 'Genetic diversity and evolution of viral populations',
'author': 'Sanjuán',
'doi-asserted-by': 'publisher',
'first-page': '53',
'journal-title': 'Encyclopedia Virol',
'key': '2022110217382301200_ciac802-B28',
'year': '2021'}],
'reference-count': 28,
'references-count': 28,
'relation': {},
'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac802/6746719'}},
'score': 1,
'short-title': [],
'source': 'Crossref',
'subject': ['Infectious Diseases', 'Microbiology (medical)'],
'subtitle': [],
'title': 'Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 '
'(SARS-CoV-2) Omicron-Infected Immunocompromised Patients',
'type': 'journal-article'}
